Membership of the Royal Colleges of Surgeons (MRCS) Practice Exam

FEC, which stands for a combination of the chemotherapy drugs fluorouracil, epirubicin, and cyclophosphamide, is employed in the treatment of breast cancer due to its efficacy against specific cellular mechanisms involved in tumor growth. The rationale behind using this combination is that each drug contributes uniquely to the overall anti-cancer effect.

Fluorouracil works by interfering with the synthesis of DNA and RNA, whereas epirubicin is an anthracycline that inhibits topoisomerase II, leading to disruption of DNA replication. Cyclophosphamide is an alkylating agent, which cross-links DNA, ultimately leading to cell death. This synergistic effect enhances the overall potency of the regimen against different subtypes of breast cancer.

Combining these agents provides a broader therapeutic approach, targeting cells that may be resistant to one single agent alone. This makes FEC effective for treating various breast cancer profiles, thus improving outcomes for patients. The effectiveness of this combination is particularly significant, as it has shown beneficial results in both premenopausal and postmenopausal women.

While FEC is effective against both estrogen receptor-positive and negative cancers, and is appropriate for different patient demographics, its primary strength lies in